Tatyana Korolenko
Institute of Physiology and Fundamental Medicine SB RAMS, Russia
Title: Serum cystatin C, an index of renal dysfunction, as a marker in ischemic heart disease
Biography
Biography: Tatyana Korolenko
Abstract
Objectives: To investigate whether patients with ischemic heart disease display altered serum cystatin C related to impaired renal function and/or as a possible biomarker of acute ischemia. Background: Cystatin C, a well known index of renal dysfunction, more efficient than creatinine, was recently suggested as a candidate biomarker in cardiovascular pathology. However, the precise role of cystatin C in cardiovascular diseases in acute myocardial infarction (MI) is not studied enough. The aim: to evaluate serum cystatin C in patients with ischemic heart disease in dynamics of myocardial infarction development. Methods: Forty-two male patients (62 ± 5.0 years) were enrolled in a study from Scientific Center of Experimental and Clinical Medicine of Novosibirsk. The control group consisted of 80 healthy persons of the appropriate age. Serum hs-CRP, D-dimer, cystatin C, creatinin, urea, lipid profile, LDH, CPK, CPK-MB were measured with help of Architect 8000 (Abbott, USA) and Access-2 (Beackman Coulter, USA), pro-BNP by ELISA method. Results: In healthy persons, aged 50-60, an elevation of serum cystatin C was shown vs. healthy persons, aged 20-40 years. In patients with ischemic heart disease, there was a significant (p < 0.001) increase in serum CPK-MD, CRP-hs D-dimer and elevated (p < 0.01) CPK, cystatin C vs the control. Positive correlation was shown between serum pro-BNP concentration and cystatin C (r = 0.57, p< 0.05) and correlation between pro-BNP and urea (r = 0.49, p< 0.05) indicating on cardio-renal syndrome development. Conclusions: Serum pro-BNP, cystatin C is elevated more significantly as compared with patients with myocardial infarction, as well as CRP-hs and D-dimer levels, indicating that these indexes can be used as predictors of increased risk of acute ischemia.